Bone Mineral Density
This week, a phase III trial for investigational drug voclosporin for lupus nephritis treatment was approved, prolonged insomnia may lead to less robust bone formation — causing osteoporosis and bone fractures — and researchers found that women who drink a moderate amount of alcohol daily have a reduced risk of developing systemic lupus erythmatosus.
Three-year fracture study examines the effects of osteoporosis drug denosumab on fractures, bone mineral density, and bone turnover markers in postmenopausal women with osteoporosis.
Prospective observational cohort study examines association between post-ICU administration of anti-fracture therapy or glucocorticoids and longitudinal changes in bone mineral density.
Testosterone treatments help improve volumetric bone mineral density and bone strength in elderly men with low testosterone.
The trabecular bone score may provides an acute, albeit indirect, measurement of bone quality in patients with type 2 diabetes.
Study examines the predictive value for vertebral fractures of bone mineral density and bone turnover markers after a 5-year drug holiday.
Long-term tenofovir treatment for hepatitis B infection is linked with abnormal phosphorus metabolism in a recent study.
Lorraine Fitzpatrick, MD, discusses updated results from the ACTIVE phase 3 clinical trial.
Higher Trabecular Bone Scores were found in postmenopausal women taking hormone replacement therapy compared with women who had never used hormone therapy.
DMARDs have been shown to be effective in halting progressive bone loss in rheumatoid arthritis.
Pediatric and adolescent patients who used stimulants to treat ADHD were found to have low bone density and bone mineral content.
Kenneth Saag, MD, president of the National Osteoporosis Foundation (NOF), co-chair of the National Bone Health Alliance, and Rheumatology Advisor advisory board member, reports on the recent changes that have led to the current state of osteoporosis treatment in the US.
Findings showing that sedentary time was not significantly linked to bone mineral density weaken the previous association between physical activity and bone mineral density.
The use of ARBs was associated with lower incidence of non-vertebral fractures than ACE inhibitors or CCBs.
Denosumab treatment led to significant increases in BMD at the lumbar spine and total hip at 12 months as compared to risedronate, both in patients receiving continuing glucocorticoid therapy and those just starting glucocorticoid therapy.
To better predict bone loss during the menopausal transition, researchers created the bone balance index using bone turnover markers to measure net bone formation.
Interval changes in bone mineral density (BMD) detected by dual-energy x-ray absorptiometry (DXA) are associated with fracture risk in women starting osteoporosis treatment
In women with premature ovarian failure, hormone replacement therapy was associated with greater increases in bone mineral density.
Lower BMD and abnormal trabecular bone microstructure with reduced bone strength was found in men with early HIV infection
After introducing the electronic health record pop-up messages, the rate of DXA prescriptions increased.
Advanced glycation endproducts were linked to reduced bone material properties in postmenopausal women with type 2 diabetes.
High doses of folic acid appeared to mitigate the effects of bone loss.
Amgen and UCB announced results from a phase 3 study evaluating romosozumab for the treatment of osteoporosis in men.
The usage of bisphosphonates decreased as a result of safety announcements issued by the United States Food and Drug Administration (FDA) regarding potential adverse effects of bisphosphonates after hip fracture.
Following a systematic evidence review, the National Osteoporosis Foundation (NOF) has developed practice guidelines based on the graded strength of current evidence.
Nearly half of all fractures in women over age 50 are associated with osteoporosis.
Investigation found that the lead author fabricated data used to support the finding that nitroglycerin improved bone density in older women.
Rheumatology Advisor Articles
- Rheumatoid Arthritis Increases Mortality Risk in Staphylococcus aureus Infections
- First Clinical Practice Guidelines for Sjögren's Syndrome Developed
- Antibiotic Resistance Problem Brought Before Congress
- FDA Delays Approval of JAK Inhibitor Baricitinib
- How Effective is RF Denervation for Symptomatic Knee OA?
- Allopurinol Use In Concomitant Gout and Diabetes Lowers Cardiovascular Event Risk
- Measuring Disease Activity in Psoriatic Arthritis
- JAK/STAT Inhibitors: A New Treatment Target for Rheumatoid Arthritis
- Biosimilar Confidence: Physician-Patient Communication Sets the Tone
- VA and DoD Practice Guideline Update: Opioids for Chronic Pain
- Leg Positioning During Lumbar DXA Does Not Impact Trabecular Bone Scores
- Should Trabecular Bone Score Be Used to Predict Fragility Fracture Risk in T1D?
- DXA for Pediatric Bone Age Assessment Yields Similar Results vs Traditional Radiography
- Remote Osteoporosis Specialist Mentoring Program Improves Physician Self-Confidence
- Increased Costs Associated With Specialists Providing Primary Care